 Crinetics Pharmaceuticals NASDAQ:CRNX was upgraded by equities research analysts at BidaskClub from a sell rating to a hold rating in a research note issued on Thursday, BidAskClub reports. Other research analysts have also issued reports about the stock. Cantor Fitzgerald reiterated an overweight rating on shares of Crinetics Pharmaceuticals in a research note on Wednesday, ... 